Tislelizumab plus nimotuzumab is effective against recurrent or metastatic oral squamous cell carcinoma among patients with a performance status score ≥ 2: a retrospective study

Overview of attention for article published in Frontiers in oncology, January 2024

Altmetric Badge

Mentioned by

twitter: 2 X users

Readers on

mendeley: 5 Mendeley

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 23,767 followers.

Tislelizumab plus nimotuzumab is effective against recurrent or metastatic oral squamous cell carcinoma among patients with a performance status score ≥ 2: a retrospective study: Objectives The efficacy of treatments targeting…… #oncology https://t.co/Zx

18 Jan 2024

Reply Repost Favourite

New research: Tislelizumab plus nimotuzumab is effective against recurrent or metastatic oral squamous cell carcinoma among patients with a performance status score ≥ 2: a retrospective study: Objectives The efficacy of treatments targeting… https://t.co/

16 Jan 2024

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.